BioMarin Pharmaceutical (BMRN) Stock Price, News & Analysis

Company Overview

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Key Stats

• Today's Range: $70.83 to $71.59
• 50-Day Range: $61.25 to $72.23
• 52-Week Range: $60.63 to $94.85
• Volume: 44,326 shs
• Average Volume: 1.77 million shs
• Market Capitalization: $13.57 billion
• P/E Ratio: 32.37
• Dividend Yield: N/A
• Price Target: $94.00
• Consensus Rating: Moderate Buy

BioMarin Pharmaceutical Stock Analysis - MarketRank™

BioMarin Pharmaceutical scored higher than 100% of companies evaluated by MarketBeat, and ranked 3rd out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

BioMarin Pharmaceutical has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 17 buy ratings, 7 hold ratings, and no sell ratings.

Amount of Analyst Coverage

BioMarin Pharmaceutical has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 38.41%

Earnings Growth

Earnings for BioMarin Pharmaceutical are expected to grow by 38.41% in the coming year, from $3.15 to $4.36 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of BioMarin Pharmaceutical is 32.37, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 23.75.

Price to Earnings Ratio vs. Sector

The P/E ratio of BioMarin Pharmaceutical is 32.37, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 24.00.

Price to Earnings Growth Ratio

BioMarin Pharmaceutical has a PEG Ratio of 0.61. PEG Ratios below 1 indicate that a company could be undervalued.

Price to Book Value per Share Ratio

BioMarin Pharmaceutical has a P/B Ratio of 2.40. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.27% of the float of BioMarin Pharmaceutical has been sold short.

Short Interest Ratio / Days to Cover

BioMarin Pharmaceutical has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in BioMarin Pharmaceutical has recently decreased by 5.15%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BioMarin Pharmaceutical does not currently pay a dividend.

Dividend Growth

BioMarin Pharmaceutical does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.3 / 5
• Environmental Score: -2.93

Percentage of Shares Shorted

2.27% of the float of BioMarin Pharmaceutical has been sold short.

Short Interest Ratio / Days to Cover

BioMarin Pharmaceutical has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in BioMarin Pharmaceutical has recently decreased by 5.15%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 4.0 / 5
• News Sentiment: 1.13

News Sentiment

BioMarin Pharmaceutical has a news sentiment score of 1.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.78 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 28 news articles for BioMarin Pharmaceutical this week, compared to 10 articles on an average week.

Search Interest

17 people have searched for BMRN on MarketBeat in the last 30 days. This is an increase of 183% compared to the previous 30 days.

MarketBeat Follows

15 people have added BioMarin Pharmaceutical to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, BioMarin Pharmaceutical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $91,903.00 in company stock.

Percentage Held by Insiders

Only 1.85% of the stock of BioMarin Pharmaceutical is held by insiders.

Percentage Held by Institutions

98.71% of the stock of BioMarin Pharmaceutical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

BMRN Stock Analysis - Frequently Asked Questions

How have BMRN shares performed this year?

BioMarin Pharmaceutical's stock was trading at $65.73 at the beginning of 2025. Since then, BMRN shares have increased by 8.3% and is now trading at $71.1530.
View the best growth stocks for 2025 here.

How were BioMarin Pharmaceutical's earnings last quarter?

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced its quarterly earnings results on Wednesday, February, 19th. The biotechnology company reported $0.72 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.54 by $0.18. The biotechnology company had revenue of $747.31 million for the quarter, compared to the consensus estimate of $711.05 million. BioMarin Pharmaceutical had a net margin of 14.96% and a trailing twelve-month return on equity of 9.91%.

Who are BioMarin Pharmaceutical's major shareholders?

BioMarin Pharmaceutical's top institutional investors include Vanguard Group Inc. (10.16%), Primecap Management Co. CA (9.54%), Dodge & Cox (7.74%) and Capital Research Global Investors (6.82%). Insiders that own company stock include Jean Jacques Bienaime, Henry J Fuchs, Richard A Meier, Jeffrey Robert Ajer, Brian Mueller, Charles Greg Guyer, George Eric Davis, V Bryan Lawlis, Erin Burkhart and Mark J Alles.
View institutional ownership trends.

How do I buy shares of BioMarin Pharmaceutical?

Shares of BMRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of BioMarin Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that BioMarin Pharmaceutical investors own include Puma Biotechnology (PBYI), Incyte (INCY), NVIDIA (NVDA), Meta Platforms (META), First Solar (FSLR), (MDVN) (MDVN) and Broadcom (AVGO).

Company Calendar

• Last Earnings: 2/19/2025
• Today: 3/18/2025
• Next Earnings (Estimated): 4/23/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:BMRN
• CIK: 1048477
• Web: www.bmrn.com
• Phone: (415) 506-6700
• Fax: 415-382-7889
• Employees: 3,401
• Year Founded: 1997

Price Target and Rating

• Average Stock Price Target: $94.00
• High Stock Price Target: $126.00
• Low Stock Price Target: $65.00
• Potential Upside/Downside: +31.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.71
• Research Coverage: 24 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $2.20
• Trailing P/E Ratio: 32.52
• Forward P/E Ratio: 22.71
• P/E Growth: 0.61
• Net Income: $167.65 million
• Net Margins: 14.96%
• Pretax Margin: 18.98%
• Return on Equity: 9.91%
• Return on Assets: 7.65%

Debt

• Debt-to-Equity Ratio: 0.11
• Current Ratio: 5.33
• Quick Ratio: 2.62

Sales & Book Value

• Annual Sales: $2.85 billion
• Price / Sales: 4.78
• Cash Flow: $3.38 per share
• Price / Cash Flow: 21.17
• Book Value: $29.69 per share
• Price / Book: 2.41

Miscellaneous

• Outstanding Shares: 190,777,000
• Free Float: 187,057,000
• Market Cap: $13.65 billion
• Optionable: Optionable
• Beta: 0.33